8-K: Oncotelic Therapeutics Secures $178K Via Convertible Note

Oncotelic Therapeutics has entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a convertible promissory note for $178,410 and commitment shares.

Summary

• On August 3, 2026, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP.
• The company issued a convertible promissory note for $178,410, which carries a 12% annual interest rate and a 12% original issue discount.
• The note matures one year from the agreement date or upon acceleration due to an Event of Default.
• Pacific Pier Capital II, LP can convert the note's principal and accrued interest into common stock at a fixed price of $0.06 per share or 85% of the lowest traded price over ten trading days prior to conversion, subject to adjustments.
• The company also issued 500,000 shares of common stock as commitment shares to Pacific Pier.
• The issuance is exempt from registration under the Securities Act of 1933, relying on Section 4(a)(2).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the dilutive nature of the convertible note and the fixed conversion price potentially being unfavorable in a volatile market.

Positives

• Secured immediate funding of $178,410 to support operations.
• The convertible note provides flexibility for future conversion into equity.

Negatives

• The convertible note has a 12% original issue discount and a 12% annual interest rate, increasing the cost of capital.
• The issuance of 500,000 commitment shares represents immediate dilution to existing shareholders.
• The conversion price is fixed at $0.06 per share or 85% of the lowest traded price, which could be significantly below future market prices, leading to substantial dilution.
• Default interest rate is 16%, indicating a higher cost if the company faces financial distress.

Risks

• Potential for significant dilution of common stock if the conversion price is substantially lower than the market price.
• Risk of default if the company cannot meet its obligations, leading to accelerated repayment at a higher interest rate.
• The fixed conversion price may not reflect the true market value of the common stock at the time of conversion.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. The primary outlook relates to the conversion mechanism of the note and potential future equity issuance.

Management Comments

• The company entered into a Securities Purchase Agreement and issued a convertible promissory note and commitment shares.
• The issuance of the note and shares is exempt from registration under the Securities Act of 1933.

Industry Context

StockSavvy.ai notes that the use of convertible notes is common for early-stage or development-stage biotechnology companies seeking to finance operations and research without immediate equity dilution at potentially unfavorable valuations. However, the terms of this note, including the discount and conversion price, suggest a need for capital that may be viewed negatively by the market.

Comparison to Industry Standards

• Convertible notes are a standard financing instrument in the biotech sector, often used by companies with limited operating history or during clinical development phases.
• Typical original issue discounts for such notes can range from 5% to 20%, with 12% falling within this range.
• Interest rates on convertible notes in this sector often range from 8% to 15%, making the 12% rate comparable.
• Conversion price mechanisms vary widely, but a fixed price or a discount to market price are common. The inclusion of both options here is not unusual, but the specific values are critical to assessing dilution.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of commitment shares and potential future conversion of the note.
• Creditors and noteholders are subject to the terms of the convertible note, including interest rates and default provisions.

Next Steps

• Pacific Pier Capital II, LP may convert the convertible promissory note into shares of common stock.
• The company will continue its operations, potentially utilizing the raised capital for research and development or other corporate purposes.

Key Dates

Recommendation

The financing provides necessary capital but comes with significant dilution risks and unfavorable terms, suggesting a cautious approach. While not a strong sell due to the capital infusion, the dilutive nature warrants a hold rather than a buy until the company demonstrates improved financial performance or more favorable financing terms.

Keywords

Convertible Note, Securities Purchase Agreement, Equity Financing, Dilution, Capital Raise, Biotechnology